Prenatal Concentrations of Perfluoroalkyl Substances and Maternal Beta Cell Function at 7 to 9 Years of Follow-Up.

IF 5.1 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Journal of Clinical Endocrinology & Metabolism Pub Date : 2025-11-18 DOI:10.1210/clinem/dgaf143

Jana Palaniyandi, Jennifer E Bruin, Mandy Fisher, Michael M Borghese, Myriam P Hoyeck, Constadina Panagiotopoulos, Jillian Ashley-Martin

{"title":"Prenatal Concentrations of Perfluoroalkyl Substances and Maternal Beta Cell Function at 7 to 9 Years of Follow-Up.","authors":"Jana Palaniyandi, Jennifer E Bruin, Mandy Fisher, Michael M Borghese, Myriam P Hoyeck, Constadina Panagiotopoulos, Jillian Ashley-Martin","doi":"10.1210/clinem/dgaf143","DOIUrl":null,"url":null,"abstract":"Context: Epidemiological evidence regarding prenatal per- and polyfluoroalkyl substance (PFAS) exposure and long-term maternal metabolic health outcomes is lacking.Objective: Quantify associations between prenatal PFAS concentrations and maternal metabolic biomarkers of glucose homeostasis 7 to 9 years later.Methods: We measured second trimester plasma concentrations of 9 PFAS in participants enrolled in the Maternal-Infant Research on Environmental Chemicals (MIREC) study. We measured individual biomarkers of glucose homeostasis (fasting intact proinsulin, C-peptide, insulin, glucose, and hemoglobin A1C levels) in samples collected 7 to 9 years after the MIREC pregnancy (n = 258) and derived indicators of pancreatic beta cell function (proinsulin to insulin [PI:INS], proinsulin to C-peptide [PI:CP] ratios) and insulin resistance (homeostatic model assessment for insulin resistance [HOMA-IR], triglyceride-glucose index). Using multivariable linear regression models, we quantified the percent change in each outcome per doubling of individual PFAS concentrations. We used quantile g-computation and weighted quantile sum regression to evaluate the mixture of PFAS.Results: Prenatal perfluorononanoic acid and perfluorodecanoic acid concentrations were associated with 13.9% (95% CI: 0.8, 28.8) and 10.5% (95% CI: -1.0, 23.4) higher HOMA-IR values as well as 11.9% (95% CI: 0.1, 25.1) and 8.9% (95% CI: -1.5, 20.3) higher fasting insulin concentrations, respectively. A doubling of perfluorooctanoic acid concentrations was associated with increases in intact proinsulin concentrations (12.8% [95% CI: -3.5, 31.8]) and beta cell function ratios (PI:INS: 11.5% [95% CI: -4.4, 30.1]; PI:CP: 13.5% [95% CI: -2.4, 32.0]).Conclusion: Prenatal exposure to PFAS may impact long-term maternal insulin resistance and beta cell function, key risk factors for type 2 diabetes. These associations differ by specific PFAS.","PeriodicalId":50238,"journal":{"name":"Journal of Clinical Endocrinology & Metabolism","volume":" ","pages":"e4221-e4231"},"PeriodicalIF":5.1000,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972668/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf143","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Epidemiological evidence regarding prenatal per- and polyfluoroalkyl substance (PFAS) exposure and long-term maternal metabolic health outcomes is lacking.

Objective: Quantify associations between prenatal PFAS concentrations and maternal metabolic biomarkers of glucose homeostasis 7 to 9 years later.

Methods: We measured second trimester plasma concentrations of 9 PFAS in participants enrolled in the Maternal-Infant Research on Environmental Chemicals (MIREC) study. We measured individual biomarkers of glucose homeostasis (fasting intact proinsulin, C-peptide, insulin, glucose, and hemoglobin A1C levels) in samples collected 7 to 9 years after the MIREC pregnancy (n = 258) and derived indicators of pancreatic beta cell function (proinsulin to insulin [PI:INS], proinsulin to C-peptide [PI:CP] ratios) and insulin resistance (homeostatic model assessment for insulin resistance [HOMA-IR], triglyceride-glucose index). Using multivariable linear regression models, we quantified the percent change in each outcome per doubling of individual PFAS concentrations. We used quantile g-computation and weighted quantile sum regression to evaluate the mixture of PFAS.

Results: Prenatal perfluorononanoic acid and perfluorodecanoic acid concentrations were associated with 13.9% (95% CI: 0.8, 28.8) and 10.5% (95% CI: -1.0, 23.4) higher HOMA-IR values as well as 11.9% (95% CI: 0.1, 25.1) and 8.9% (95% CI: -1.5, 20.3) higher fasting insulin concentrations, respectively. A doubling of perfluorooctanoic acid concentrations was associated with increases in intact proinsulin concentrations (12.8% [95% CI: -3.5, 31.8]) and beta cell function ratios (PI:INS: 11.5% [95% CI: -4.4, 30.1]; PI:CP: 13.5% [95% CI: -2.4, 32.0]).

Conclusion: Prenatal exposure to PFAS may impact long-term maternal insulin resistance and beta cell function, key risk factors for type 2 diabetes. These associations differ by specific PFAS.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

产前全氟烷基物质浓度与7至9年随访时母体β细胞功能

背景：关于产前全氟和多氟烷基物质（PFAS）暴露和母体长期代谢健康结果的流行病学证据缺乏。目的：量化产前PFAS浓度与7 - 9年后母体葡萄糖稳态代谢生物标志物之间的关系。方法：我们测量了参加母婴环境化学物质研究（MIREC）研究的参与者的妊娠中期血浆中9种PFAS的浓度。我们测量了MIREC妊娠后7至9年收集的样本（n = 258）中葡萄糖稳态的个体生物标志物（空腹完整的胰岛素原、c肽、胰岛素、葡萄糖和血红蛋白A1C水平），以及胰腺β细胞功能的衍生指标（胰岛素原与胰岛素[PI:INS]、胰岛素原与c肽[PI:CP]比值）和胰岛素抵抗（胰岛素抵抗的稳态模型评估[HOMA-IR]、甘油三酯-葡萄糖指数）。使用多变量线性回归模型，我们量化了单个PFAS浓度加倍时每个结果的百分比变化。我们使用分位数g计算和加权分位数和回归来评估PFAS的混合。结果：产前全氟壬烷酸和全氟癸酸浓度分别与HOMA-IR值升高13.9% （95% CI: 0.8, 28.8）和10.5% （95% CI: -1.0, 23.4）以及空腹胰岛素浓度升高11.9% （95% CI: 0.1, 25.1）和8.9% （95% CI: -1.5, 20.3）相关。全氟辛酸浓度加倍与完整胰岛素原浓度（12.8% [95% CI: -3.5, 31.8]）和β细胞功能比率（PI:INS: 11.5% [95% CI: -4.4, 30.1]）的增加有关；Pi: cp: 13.5% [95% ci: -2.4, 32.0])。结论：产前暴露于PFAS可能影响母体长期胰岛素抵抗和β细胞功能，这是2型糖尿病的关键危险因素。这些关联因具体的PFAS而异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Clinical Endocrinology & Metabolism 医学-内分泌学与代谢

CiteScore

11.40

自引率

5.20%

发文量

673

审稿时长

1 months

期刊介绍： The Journal of Clinical Endocrinology & Metabolism is the world"s leading peer-reviewed journal for endocrine clinical research and cutting edge clinical practice reviews. Each issue provides the latest in-depth coverage of new developments enhancing our understanding, diagnosis and treatment of endocrine and metabolic disorders. Regular features of special interest to endocrine consultants include clinical trials, clinical reviews, clinical practice guidelines, case seminars, and controversies in clinical endocrinology, as well as original reports of the most important advances in patient-oriented endocrine and metabolic research. According to the latest Thomson Reuters Journal Citation Report, JCE&M articles were cited 64,185 times in 2008.